| abstract |
The present invention provides a novel CCR9 receptor inhibitor effective for a disease mediated by a CCR9 receptor such as an inflammatory disease. The following structural formula: Or a pharmaceutically acceptable salt, solvate or hydrate thereof. (Y is C (O), O, S, S (O) or S (O) 2 ; X 1 , X 2 and X 3 are N or CR. R 1 is H or a substituent. R 6 is H, an aliphatic carbonyl group, or an aliphatic ester; Ar 1 and Ar 2 are an aryl group or a heteroaryl group.) [Selection figure] None |